Calvary Mater Newcastle Hospital

Randomized phase III trial with a factorial design assessing the efficacy and safety of darolutamide and stereotactic dose-escalated radiotherapy in patients with high-risk localized prostate cancer: the PEACE 7 (GETUG-AFU 45) study protocol

Approximately 15% of patients with localized prostate cancer harbor high risk features. Nowadays, the standard of care for such patients is the combination of androgen deprivation therapy (ADT) plus radiotherapy (hypofractionated or conventional dose escalated radiotherapy). A su...

ACPSEM guideline regarding the adoption of the IAEA TRS-398 Code of Practice Revision 1

Abstract The IAEA Technical Report Series 398 Code of Practice for the determination of absorbed dose in external beam radiotherapy was endorsed at the Engineers and Physical Scientists in Medicine (EPSM) conference in 2001 and has been widely adopted in Australia and New Zealand...

A mixed methods evaluation of pleural procedural experience and training in intensive care trainees

Abstract Background Pleural procedures are key skills for Intensive Care Unit (ICU) doctors but can be associated with serious complications. We aimed to explore ICU junior doctors’ training, experience, and confidence in performing pleural procedures. Methods The study was a pro...

Impact of Response to Hypomethylating Agent‐Based Therapy on Survival Outcomes in the Context of Baseline Clinical‐Molecular Risk and Transplant Status in Patients With Higher‐Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS)

Baseline IPSS-M risk, response to hypomethylating agent (HMA) therapy, and receipt of allogeneic stem cell transplant (allo-HCT) have all been individually shown to impact overall survival (OS) in patients with myelodysplastic syndromes (MDS). However, the prognostic impact of re...